7 / 26
Journal of Transmitted Diseases and Immunity
ISSN: 2573-0320
Page 65
Volume 4
May 10-11, 2018
Frankfurt, Germany
Immunology Research 2018
Tissue Science 2018
JOINT EVENT
2 2
n d
E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology and
Evolution of Infectious Diseases
&
1 2
t h
E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Tissue Engineering and
Regenerative Medicine
C
urrently, perfluorodecalin (PFD) and perfluorooctyl bromide
(PFOB) are the majorly used perfluorocarbons in the field of
artificial oxygen carriers. So far, in our investigations only PFD
has been employed as core material of albumin-derived artificial
oxygen carriers (A-AOCs). This led to the question of whether
PFOB would display an equally safe alternative in A-AOCs. To
investigate toxicity, we studied A-AOCs with a PFOB-core in a
top load model (TL) and compared the data with results from
our previous studies with a PFD-core. TL (+1/6 of blood volume)
experiments with 16 healthy Wistar rats were performed with
and without (control) A-AOCs (17 vol. %), respectively. After the
infusion period (30 min) rats were further observed up to 180
min. During TL systemic parameters, plasma enzyme activities
and acid base status were continuously monitored. To confirm
hemolysis obtained in the
in vivo
model, supporting
in vitro
studies were performed additionally: whole blood was incubated
varying temperature, A-AOCs-concentration and mechanical
stress. Blood pressure showed a transient drop during infusion
of A-AOCs but was unaffected in the control group. Compared
to control animals the PFOB-group displayed increased plasma
enzyme activities. All effects after application of only 17 vol. %
A-AOCs with PFOB-core were considerably more pronounced
compared to 32 vol. % A-AOCs with PFD-core. Furthermore,
hemolysis caused by A-AOCs with PFOB-core was significantly
more distinct compared to A-AOCs with PFD-core. In conclusion,
PFOB should be avoided as core material for A-AOCs because of
distinct side-effects already occurring at low dosage.
Biography
Alexandra Scheer completed her Master’s degree in Medical Biology in
2015. Since October 2015, she has been working on her Doctoral thesis at
Institute of Physiological Chemistry-University Hospital Essen, Germany, in
the working group of Dr Katja B Ferenz. Within the scope of this work, she
is involved in the development and characterization of artificial oxygen car-
riers. Since February 2018, she followed Katja B Ferenz in the Institute of
Physiology at University Hospital Essen, Germany, to continue her work. Her
research interests include “Artificial oxygen carriers, biomaterials, nanoparti-
cles and perfluorocarbons”.
alexandra.scheer@uk-essen.dePerfluorooctyl bromide vs. perfluorodecalin: Which
perfluorocarbon is preferable for albumin-derived artificial
oxygen carriers?
Alexandra Scheer
1
, Anna Wrobeln
2
, Michael Kirsch
2
and
Katja B Ferenz
2
1
University Hospital Essen, Germany
2
University of Duisburg-Essen, Germany
Alexandra Scheer et al., J Transm Dis Immun 2018, Volume 2
DOI: 10.21767/2573-0320-C2-006